Fundz Deep Dive
Everything you need to win Amicus Therapeutics — in one platform.
Who to reach, what to say, and why now on Amicus Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Amicus Therapeutics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
BioMarin Pharmaceutical Agrees to Acquire Amicus Therapeutics for $14.50 per Share.
Dec 22, 2025•6 months ago
Contract Type
agreement
PhiladelphiaBiotechnologyHealth CareTherapeuticsDescription
On December 19, 2025, BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction, valuing Amicus at approximately $4.8 billion. The deal is expected to close in Q2 2026, pending shareholder approval and regulatory clearances.
Related People
Suggested for you
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months